Skip to main content
Top
Published in: Clinical and Translational Allergy 1/2015

Open Access 01-12-2015 | Review

Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose

Authors: Pascal Demoly, Gianni Passalacqua, Moises A. Calderon, Tarik Yalaoui

Published in: Clinical and Translational Allergy | Issue 1/2015

Login to get access

Abstract

Sublingual immunotherapy (SLIT) is an effective and well-tolerated method of treating allergic respiratory diseases associated with seasonal and perennial allergens. In contrast to the subcutaneous route, SLIT requires a much greater amount of antigen to achieve a clinical effect. Many studies have shown that SLIT involves a dose–response relationship, and therefore it is important to use a proven clinically effective dose from the onset of treatment, because low doses are ineffective and very high doses may increase the risk of side effects. A well-defined standardization of allergen content is also crucial to ensure consistent quality, potency and appropriate immunomodulatory action of the SLIT product. Several methods of measuring antigenicity are used by manufacturers of SLIT products, including the index of reactivity (IR), standardized quality tablet unit, and bioequivalent allergy unit. A large body of evidence has established the 300 IR dose of SLIT as offering optimal efficacy and tolerability for allergic rhinitis due to grass and birch pollen and HDM, and HDM-induced moderate, persistent allergic asthma. The 300 IR dose also offers consistency of dosing across a variety of different allergens, and is associated with higher rates of adherence and patient satisfaction. Studies in patients with grass pollen allergies showed that the 300 IR dose has a rapid onset of action, is effective in both adults and children in the short term and, when administered pre-coseasonally in the long term, and maintains the clinical benefit, even after cessation of treatment. In patients with HDM-associated AR and/or asthma, the 300 IR dose also demonstrated significant improvements in symptoms and quality of life, and significantly decreased use of symptomatic medication. The 300 IR dose is well tolerated, with adverse events generally being of mild or moderate severity, declining in frequency and severity over time and in the subsequent courses. We discuss herein the most important factors that affect the selection of the optimal dose of SLIT with natural allergens, and review the rationale and evidence supporting the use of the 300 IR dose.
Literature
1.
go back to reference Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6:11–23.PubMedCrossRef Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6:11–23.PubMedCrossRef
2.
go back to reference Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.PubMedCrossRef Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.PubMedCrossRef
3.
go back to reference Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician. 2010;81:1440–6.PubMed Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician. 2010;81:1440–6.PubMed
4.
go back to reference Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1–84.PubMedCrossRef Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1–84.PubMedCrossRef
5.
go back to reference Devillier P, Dreyfus JF, Demoly P, Calderon MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med. 2014;12:71.PubMedPubMedCentralCrossRef Devillier P, Dreyfus JF, Demoly P, Calderon MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med. 2014;12:71.PubMedPubMedCentralCrossRef
6.
go back to reference Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy. 2010;40:385–97.PubMedCrossRef Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy. 2010;40:385–97.PubMedCrossRef
7.
go back to reference Incorvaia C. Preventive capacity of allergen immunotherapy on the natural history of allergy. J Prev Med Hyg. 2013;54:71–4.PubMed Incorvaia C. Preventive capacity of allergen immunotherapy on the natural history of allergy. J Prev Med Hyg. 2013;54:71–4.PubMed
8.
go back to reference Lin SY, Erekosima N, Suarez-Cuervo C et al. Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review. Rockville: Rockville (MD); 2013. Lin SY, Erekosima N, Suarez-Cuervo C et al. Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review. Rockville: Rockville (MD); 2013.
9.
go back to reference Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67:302–11.PubMedCrossRef Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67:302–11.PubMedCrossRef
10.
go back to reference Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.PubMedPubMedCentralCrossRef Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.PubMedPubMedCentralCrossRef
11.
go back to reference Demoly P, Calderon MA. Dosing and efficacy in specific immunotherapy. Allergy. 2011;66(Suppl 95):38–40.PubMedCrossRef Demoly P, Calderon MA. Dosing and efficacy in specific immunotherapy. Allergy. 2011;66(Suppl 95):38–40.PubMedCrossRef
12.
go back to reference Meadows A, Kaambwa B, Novielli N et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013;17:vi, xi–xiv, 1–322. Meadows A, Kaambwa B, Novielli N et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013;17:vi, xi–xiv, 1–322.
13.
go back to reference Demoly P, Calderon MA, Casale TB, et al. The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis. Clin Transl Allergy. 2015;5:18.PubMedPubMedCentralCrossRef Demoly P, Calderon MA, Casale TB, et al. The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis. Clin Transl Allergy. 2015;5:18.PubMedPubMedCentralCrossRef
14.
go back to reference Calderon MA, Larenas D, Kleine-Tebbe J, et al. European Academy of Allergy and Clinical Immunology task force report on ‘dose-response relationship in allergen-specific immunotherapy’. Allergy. 2011;66:1345–59.PubMedCrossRef Calderon MA, Larenas D, Kleine-Tebbe J, et al. European Academy of Allergy and Clinical Immunology task force report on ‘dose-response relationship in allergen-specific immunotherapy’. Allergy. 2011;66:1345–59.PubMedCrossRef
15.
go back to reference Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(1608–1614):e1606. Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(1608–1614):e1606.
16.
go back to reference Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:1338–45.PubMedCrossRef Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:1338–45.PubMedCrossRef
17.
go back to reference Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64:1394–401.PubMedCrossRef Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64:1394–401.PubMedCrossRef
18.
go back to reference Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014;69:1181–8.PubMedCrossRef Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014;69:1181–8.PubMedCrossRef
19.
go back to reference Worm M, Rak S, de Blay F, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy. 2014;4:7.PubMedPubMedCentralCrossRef Worm M, Rak S, de Blay F, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy. 2014;4:7.PubMedPubMedCentralCrossRef
20.
go back to reference Larenas-Linnemann D, Cox LS, et al. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol. 2008;100:137–45.PubMedCrossRef Larenas-Linnemann D, Cox LS, et al. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol. 2008;100:137–45.PubMedCrossRef
21.
go back to reference Frati F, Scurati S, Puccinelli P, et al. Development of an allergen extract for sublingual immunotherapy–evaluation of Staloral. Expert Opin Biol Ther. 2009;9:1207–15.PubMedCrossRef Frati F, Scurati S, Puccinelli P, et al. Development of an allergen extract for sublingual immunotherapy–evaluation of Staloral. Expert Opin Biol Ther. 2009;9:1207–15.PubMedCrossRef
22.
go back to reference Pajno GB, Caminiti L, Crisafulli G, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol. 2011;22:803–7.PubMedCrossRef Pajno GB, Caminiti L, Crisafulli G, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol. 2011;22:803–7.PubMedCrossRef
23.
go back to reference Stelmach I, Kaluzinska-Parzyszek I, Jerzynska J, et al. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy. 2012;67:312–20.PubMedCrossRef Stelmach I, Kaluzinska-Parzyszek I, Jerzynska J, et al. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy. 2012;67:312–20.PubMedCrossRef
24.
go back to reference Zuberbier T, Bachert C, Bousquet PJ, et al. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65:1525–30.PubMedCrossRef Zuberbier T, Bachert C, Bousquet PJ, et al. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65:1525–30.PubMedCrossRef
27.
go back to reference Archila LD, DeLong JH, Wambre E, et al. Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy. Clin Exp Allergy. 2014;44:986–98.PubMedPubMedCentralCrossRef Archila LD, DeLong JH, Wambre E, et al. Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy. Clin Exp Allergy. 2014;44:986–98.PubMedPubMedCentralCrossRef
28.
go back to reference Zuberbier T, Canonica GW, da Silva B. Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases. J Dtsch Dermatol Ges. 2012;10:879–85.PubMed Zuberbier T, Canonica GW, da Silva B. Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases. J Dtsch Dermatol Ges. 2012;10:879–85.PubMed
29.
30.
go back to reference Kaul S, May S, Luttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy. 2011;66:753–64.PubMedCrossRef Kaul S, May S, Luttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy. 2011;66:753–64.PubMedCrossRef
31.
go back to reference Larsen TH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy—a phase-1 study. Allergy. 2006;61:1173–6.PubMedCrossRef Larsen TH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy—a phase-1 study. Allergy. 2006;61:1173–6.PubMedCrossRef
32.
go back to reference Malling HJ, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009;39:387–93.PubMedPubMedCentralCrossRef Malling HJ, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009;39:387–93.PubMedPubMedCentralCrossRef
33.
go back to reference Didier A, Melac M, Montagut A, et al. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy. 2009;64:166–71.PubMedCrossRef Didier A, Melac M, Montagut A, et al. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy. 2009;64:166–71.PubMedCrossRef
34.
go back to reference Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130(1327–1334):e1321. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130(1327–1334):e1321.
35.
go back to reference Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(160–166):e163. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(160–166):e163.
36.
go back to reference Didier A, Malling HJ, Worm M, et al. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12.PubMedPubMedCentralCrossRef Didier A, Malling HJ, Worm M, et al. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12.PubMedPubMedCentralCrossRef
37.
go back to reference Horak F, Zieglmayer P, Zieglmayer R et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471–7, 477 e471. Horak F, Zieglmayer P, Zieglmayer R et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471–7, 477 e471.
39.
go back to reference Ferrés J, Justicia JL, García MP, et al. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr). 2011;39:122–7.CrossRef Ferrés J, Justicia JL, García MP, et al. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr). 2011;39:122–7.CrossRef
40.
go back to reference Sieber J, Neis M, Brehler R, et al. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study. Expert Opin Drug Saf. 2012;11:7–13.PubMedCrossRef Sieber J, Neis M, Brehler R, et al. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study. Expert Opin Drug Saf. 2012;11:7–13.PubMedCrossRef
41.
go back to reference Didier A, Bons B. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. Expert Opin Drug Saf. 2015;14:777–88.PubMedCrossRef Didier A, Bons B. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. Expert Opin Drug Saf. 2015;14:777–88.PubMedCrossRef
42.
go back to reference Lyseng-Williamson KA. Standardized sublingual allergen extract solution (Staloral®): a guide to its use as allergen-specific immunotherapy. Drugs Ther Perspect. 2014;. doi:10.1007/s40267-40014-40165-x. Lyseng-Williamson KA. Standardized sublingual allergen extract solution (Staloral®): a guide to its use as allergen-specific immunotherapy. Drugs Ther Perspect. 2014;. doi:10.​1007/​s40267-40014-40165-x.
43.
go back to reference Demoly P, Le Gall M, Roux M, Zeldin RK. Safety and tolerability of high doses of sublingual tablet of house dust mite allergen extracts in subjects with house dust mite-associated respiratory allergy. Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015, Barcelona, Spain. Demoly P, Le Gall M, Roux M, Zeldin RK. Safety and tolerability of high doses of sublingual tablet of house dust mite allergen extracts in subjects with house dust mite-associated respiratory allergy. Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015, Barcelona, Spain.
44.
go back to reference Seidenberg J, Pajno GB, Bauer CP, et al. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol. 2009;19:125–31.PubMed Seidenberg J, Pajno GB, Bauer CP, et al. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol. 2009;19:125–31.PubMed
45.
go back to reference Corzo JL, Martínez-Cañavate AM, Ramos JC et al. Estudio de tolerabilidad pauta rápida con immunoterapia sublingual con Staloral 300 Rápid® en niños. Presented at: XXXVI Congreso de la Sociedad Española de Inmunología Clínica y Alergología Pediátrica (SEICAP) 2012, Cádiz, Spain. Corzo JL, Martínez-Cañavate AM, Ramos JC et al. Estudio de tolerabilidad pauta rápida con immunoterapia sublingual con Staloral 300 Rápid® en niños. Presented at: XXXVI Congreso de la Sociedad Española de Inmunología Clínica y Alergología Pediátrica (SEICAP) 2012, Cádiz, Spain.
46.
go back to reference Trebuchon F, David M, Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy: a retrospective, observational study. Int J Immunopathol Pharmacol. 2012;25:193–206.PubMed Trebuchon F, David M, Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy: a retrospective, observational study. Int J Immunopathol Pharmacol. 2012;25:193–206.PubMed
47.
go back to reference Trebuchon F, Lheritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy. 2014;4:15.PubMedPubMedCentralCrossRef Trebuchon F, Lheritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy. 2014;4:15.PubMedPubMedCentralCrossRef
48.
go back to reference Antolin D, Valbuena T, Valls A et al. One season of treatment with 5 grass pollen tablets in adults demonstrated a reduction in disease symptoms and impacts. Findings of the SMILE study. Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting 2013, Milan, Italy. Antolin D, Valbuena T, Valls A et al. One season of treatment with 5 grass pollen tablets in adults demonstrated a reduction in disease symptoms and impacts. Findings of the SMILE study. Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting 2013, Milan, Italy.
49.
go back to reference Fernandez-Nieto M, Alvarez JA, Alvarado MI et al. What is the opinion of the patients under 5 grass pollen tablets immunotherapy? First season assessment in adults. Findings of the SMILE study. Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting 2013, Milan, Italy. Fernandez-Nieto M, Alvarez JA, Alvarado MI et al. What is the opinion of the patients under 5 grass pollen tablets immunotherapy? First season assessment in adults. Findings of the SMILE study. Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting 2013, Milan, Italy.
50.
go back to reference Lyseng-Williamson KA. Sublingual five-grass pollen tablets (Oralair®): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. Drugs Ther Perspect. 2014;. doi:10.1007/s40267-40014-40131-40267. Lyseng-Williamson KA. Sublingual five-grass pollen tablets (Oralair®): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. Drugs Ther Perspect. 2014;. doi:10.​1007/​s40267-40014-40131-40267.
51.
go back to reference Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers’ viewpoint. J Allergy Clin Immunol. 2010;126:668–9.PubMedCrossRef Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers’ viewpoint. J Allergy Clin Immunol. 2010;126:668–9.PubMedCrossRef
52.
go back to reference Frati F, Sensi L, Di Rienzo V, et al. A model for management of sublingual immunotherapy. Eur Ann Allergy Clin Immunol. 2003;35:56–60.PubMed Frati F, Sensi L, Di Rienzo V, et al. A model for management of sublingual immunotherapy. Eur Ann Allergy Clin Immunol. 2003;35:56–60.PubMed
Metadata
Title
Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose
Authors
Pascal Demoly
Gianni Passalacqua
Moises A. Calderon
Tarik Yalaoui
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Clinical and Translational Allergy / Issue 1/2015
Electronic ISSN: 2045-7022
DOI
https://doi.org/10.1186/s13601-015-0088-1

Other articles of this Issue 1/2015

Clinical and Translational Allergy 1/2015 Go to the issue